AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23475016
Drug: Combination training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination training (multimedia-based training + practical training)
Trial: 19553301
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g oil-rich fish (salmon) per week (n = 82)
Trial: 19553301
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g lean fish (cod) per week (n = 78)
Trial: 17548749
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus liothyronine
Trial: 9591932
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg imidapril once per day for 7 days
Trial: 25594526
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol, programmed to start stimulatory agents on a Friday, with oral 2mg estradiol valerate twice a day from the 2nd day of cycle until the first Friday to follow.
Trial: 25594526
Drug: Long luteal
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long luteal GnRH agonist protocol.
Trial: 25594526
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol.
Trial: 25594526
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist protocol.
Trial: 11333992
Drug: Carvedilol (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (6.25 to 50 mg twice daily)
Trial: 9284847
Drug: Pindolol with
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol with 1.5 gm ammonium chloride (NH4Cl) four times daily for 3 days
Trial: 9284847
Drug: Pindolol with
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol with 200 mg trimethoprim once daily for 3 days
Trial: 7904188
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate with aspirin
Trial: 3554082
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with 25,000 IU of retinol daily for up to 3 months
Trial: 3554082
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with 50,000 IU of retinol daily for up to 3 months
Trial: 3554082
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of retinol supplementation
Trial: 15922816
Drug: Butorphanol tartrate
RxNorm normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butorphanol tartrate (BT) nasal spray 1 mg
Trial: 15922816
Drug: Butorphanol tartrate
RxNorm normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butorphanol tartrate (BT) nasal spray 2 mg
Trial: 7883742
Drug: Electroshock therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroshock therapy
Trial: 2568348
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg and 200 mg)
Trial: 2568348
Drug: D-amphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (10 mg and 20 mg)
Trial: 29770722
Drug: Fluocinonide 0.05%
RxNorm normalized name: FLUOCINONIDE 0.05% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinonide 0.05% gel
Trial: 29770722
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate 0.1% lotion
Trial: 29770722
Drug: Fluocinonide 0.05%
RxNorm normalized name: FLUOCINONIDE 0.05% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinonide 0.05% solution
Trial: 31127666
Drug: Reprieve therapy
RxNorm normalized name: Bepreve
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reprieve therapy (with normal saline for matched volume replacement)
Trial: 31127666
Drug: Standard diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diuretic therapy
Trial: 31127666
Drug: Reprieve therapy
RxNorm normalized name: Bepreve
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reprieve therapy
Trial: 28581401
Drug: Hippocampal-sparing prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippocampal-sparing prophylactic cranial irradiation (PCI) 25 Gy/10 fractions, with a mean hippocampal dose limited to <8 Gy.
Trial: 23570586
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) at 200 or 150 mg×m(‐2)d(‐1) for 5 days, repeated every 28 days
Trial: 23570586
Drug: Semustine (Me‐CCNU)
RxNorm normalized name: Lomustine
DrugBank: Semustine (DB13647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Semustine (Me‐CCNU) at 150 mg×m(‐2)×d(‐1) once, repeated every 28 days
Trial: 25474278
Drug: Oxaliplatin and
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin and fluoropyrimidine-based chemotherapy
Trial: 25474278
Drug: 2nd and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2nd and/or 3rd line chemotherapy with irinotecan and/or cetuximab
Trial: 22508711
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (1 mU/min · kg)
Trial: 22508711
Drug: Candesartan (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (32 mg) + Insulin infusion
Trial: 21547174
Drug: Palonosetron 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 75 μg intravenously as a bolus before induction of anaesthesia
Trial: 21547174
Drug: Granisetron 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 2.5 mg intravenously as a bolus before induction of anaesthesia
Trial: 12810240
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg tid
Trial: 1806619
Drug: Clozapine, 150-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine, 150-250 mg p.d.
Trial: 1806619
Drug: Haloperidol, 20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol, 20-40 mg p.d.
Trial: 6412376
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution (group A)
Trial: 6412376
Drug: Dextrose‐electrolyte‐calcium solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose‐electrolyte‐calcium solution (group B)
Trial: 30866088
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg
Trial: 21312292
Drug: Reboxetine 8
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 8 mg/day (twice daily)
Trial: 15797959
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg daily), Vitamin D (800 IU daily), and sex steroid replacement therapy (estrogen for females, testosterone for males)
Trial: 15797959
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg daily), Vitamin D (800 IU daily), sex steroid replacement therapy (estrogen for females, testosterone for males), and six iv infusions of pamidronate (60 mg each)
Trial: 8745456
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (radiotherapy + surgery) in 46 patients
Trial: 2565582
Drug: Buspirone (acute:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (acute: 15 mg; subchronic: 5 mg t.i.d.; Day 7: 5 mg)
Trial: 2565582
Drug: Bromazepam (acute:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (acute: 6 mg; subchronic: 2 mg t.i.d.; Day 7: 2 mg)
Trial: 937075
Drug: Lanoxin tablets
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lanoxin tablets
Trial: 937075
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of digoxin
Trial: 937075
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (tablets and oral solution)
Trial: 20616624
Drug: Brief dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief dynamic therapy (BDT) added to pharmacotherapy (n = 27)
Trial: 20616624
Drug: Pharmacotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy alone (n = 30)
Trial: 17653509
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without statin
Trial: 10530677
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 600 mg, 1200 mg, or 2400 mg daily
Trial: 10530677
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 300 mg/day or 3600 mg/day
Trial: 10530677
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 300 mg/day, 900 mg/day, or 1800 mg/day
Trial: 7502570
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg piroximone
Trial: 7502570
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg piroximone
Trial: 7502570
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg piroximone
Trial: 7502570
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg piroximone
Trial: 2274638
Drug: Nadolol, 80
RxNorm normalized name: Nadolol, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol, 80 to 120 mg per day
Trial: 28820635
Drug: CIK cell
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIK cell infusion after FOLFOX4 chemotherapy
Trial: 28820635
Drug: FOLFOX4 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 chemotherapy
Trial: 16707911
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) substitution therapy for 6 months
Trial: 10486672
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (dihydropyridines, diltiazem, verapamil, bepridil)
Trial: 10486672
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (subgroup analysis in patients over 65 years old)
Trial: 10486672
Drug: Salicylates and
RxNorm normalized name: salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylates and non-steroidal anti-inflammatory drugs
Trial: 8610947
Drug: Amoxicillin, 500
RxNorm normalized name: Amoxicillin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin, 500 mg three times daily for 20 days
Trial: 8610947
Drug: Azithromycin, 500
RxNorm normalized name: Azithromycin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 500 mg once daily for 7 days
Trial: 2023353
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B sulfate, neomycin sulfate, and vancomycin hydrochloride (PNV) administered six times daily in the oropharynx.
Trial: 2023353
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered six times daily in the oropharynx.
Trial: 6758744
Drug: Conventional propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional propranolol (160 or 320 mg once daily)
Trial: 6758744
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting propranolol (160 or 320 mg once daily)
Trial: 24837493
Drug: NASHA Dx
RxNorm normalized name: brompheniramine maleate / dextromethorphan hydrobromide / pseudoephedrine hydrochloride Oral Solution [Myphetane DX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NASHA Dx injection therapy
Trial: 12237203
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of segmental and extrasegmental stimulation
Trial: 8821297
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment and cotton covers encasement
Trial: 2074254
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 1 g cefodizime
Trial: 2074254
Drug: Repeated intravenous
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated intravenous infusions of 1 g cefodizime twice daily for 4.5 days
Trial: 7044069
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg or 150 mg/day)
Trial: 7044069
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg or 150 mg/day)
Trial: 30847828
Drug: Bupropion, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion, 150 mg twice daily
Trial: 29630702
Drug: Varenicline, 1
RxNorm normalized name: Varenicline, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline, 1 mg twice daily
Trial: 30847828
Drug: Nicotine patch,
RxNorm normalized name: Nicotine Patch, 7 mg/24 hr transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch, 21 mg/day with taper (active control)
Trial: 29804407
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb761) drops oral treatment (3 times/d, 80 mg each time)
Trial: 29804407
Drug: Routine oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oxygen inhalation and appeasement treatment
Trial: 19282713
Drug: IVRA ketamine
RxNorm normalized name: Ivra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVRA ketamine (0.1 mg/kg in 1 mL of normal saline)
Trial: 19282713
Drug: Systemic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic ketamine (0.1 mg/kg in 1 mL of normal saline via peripheral IV)
Trial: 17457158
Drug: Meropenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1 g intravenously every 8 hours for 7 to 21 days)
Trial: 11050257
Drug: Early discharge
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early discharge with home treatment supported by respiratory nurses
Trial: 8923568
Drug: Mecamylamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (0, 10, or 20 mg)
Trial: 1464339
Drug: Nisoldipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (20 mg once a day for 4 weeks)
Trial: 27349951
Drug: Topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20% autologous serum eye drops (ASEs) with silicone-hydrogel soft contact lenses (SCLs)
Trial: 19396774
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract associated with hyaluronic acid ophthalmic solution (GB‐HA)
Trial: 19396774
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid ophthalmic solution (HA) alone
Trial: 15829474
Drug: Original program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original program (specific to smokers in preparation stage)
Trial: 15829474
Drug: Modified program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified program (specific to smokers in preparation stage)
Trial: 10099052
Drug: Pidotimod (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidotimod (800 mg once a day for 90 days)
Trial: 8088489
Drug: Ciprofloxacin 0.2
RxNorm normalized name: CIPROFLOXACIN 0.2/HC 1% OTIC SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 0.2 g intravenously b.i.d. + Metronidazole 0.5 g intravenously t.i.d.
Trial: 8088489
Drug: Cefoxitin 2
RxNorm normalized name: cefoxitin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2 g intravenously t.i.d. + Doxycycline 0.1 g b.i.d.
Trial: 2031201
Drug: FAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC plus lonidamine (600 mg orally daily three times a day)
Trial: 2031201
Drug: FAC (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC (standard therapy)
Trial: 7016247
Drug: Fluorescent treponemal
RxNorm normalized name: treponemic skin canker preparation, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorescent treponemal antibody‐absorption (FTA‐ABS) test
Trial: 31131640
Drug: Somatic yoga
RxNorm normalized name: Bos taurus somatic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatic yoga and meditation (SYM) intervention, twice a week for 8 weeks for 1.5 hours, with home program and journaling.
Trial: 27815483
Drug: Artificial Tear
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial Tear (AT) therapy
Trial: 24979446
Drug: Once‐daily oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once‐daily oral tenofovir disoproxil fumarate (TDF) or FTC‐TDF
Trial: 24979446
Drug: Once‐daily oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once‐daily oral tenofovir-based PrEP
Trial: 19270357
Drug: Isoflurane preconditioning
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane preconditioning (1.0 minimum alveolar concentration end-tidal, approximately 1.1% to 1.2%) administered for 30 min followed by a 15 min washout period before CPB.
Trial: 19270357
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no isoflurane inhalation).
Trial: 17479540
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride extended-release (MXR) 1000 mg single dose
Trial: 17479540
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride extended-release (MXR) 1000 mg/d for 9 days
Trial: 17479540
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride immediate-release (MIR) 1000 mg single dose
Trial: 17479540
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride immediate-release (MIR) 1000 mg/d for 14 days
Trial: 8496328
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week for 1 year)
Trial: 31230988
Drug: Movement System
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement System Impairment-Based classification treatment
Trial: 28006108
Drug: Digitoxin 0.1
RxNorm normalized name: digitoxin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitoxin 0.1 mg daily for 28 days
Trial: 28006108
Drug: Digitoxin 0.05
RxNorm normalized name: digitoxin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitoxin 0.05 mg daily for 28 days
Trial: 21926600
Drug: Granulocyte-macrophage colony
RxNorm normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony stimulating factor (250 μg/M)
Trial: 31361303
Drug: Pegvisomant therapy
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegvisomant therapy
Trial: 7933823
Drug: Recombinant hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hirudin (0.08 mg/kg)
Trial: 3234411
Drug: Diltiazem 240
RxNorm normalized name: diltiazem 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 240 mg (60 mg q.i.d.)
Trial: 3234411
Drug: Metoprolol 200
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 200 mg (100 mg b.i.d.)
Trial: 2058318
Drug: Ketanserin (S2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (S2-receptor blocker) with concurrent physiotherapy
Trial: 332188
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid combined with fentonium bromide (125 mg and 20 mg respectively, 3-4 capsules daily for 14 days)